Lilly sues online vendors, medical spa over copycat weight-loss drugs

Lilly sues online vendors, medical spa over copycat weight-loss drugs


An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan McDermid | Reuters

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.

The new lawsuits, which name Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine of Nevada, are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month.

Lilly said these lawsuits were not in any way contingent on tirzepatide coming off of that list and could have been filed regardless of whether supply issues had been resolved.

Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Medical spa Genesis sells and administers compounded versions of the drug, according to the lawsuits.

Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes.

The lawsuits were filed in federal and state courts in Indiana, Texas and Washington, accusing each defendant of false advertising and promotion. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit.

“Lilly is bringing these actions to protect American consumers from direct patient safety risks,” said a spokesperson for the drugmaker, adding that the defendants were making false claims about efficacy or safety, and misleading consumers about the clinical data used to back them.

The Indianapolis-based drugmaker has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro.

In its most recent filings, Lilly said MangoRx was selling an oral version of tirzepatide branded as Trim, despite the lack of any study showing that formulation to be safe and effective. The FDA to date has only approved tirzepatide as an injectable drug.

After Lilly sent Pivotal Peptides a cease and desist letter, the vendor changed its website to say it was under maintenance and altered its operations to sell via email, social media, and word of mouth, according to the drugmaker’s lawsuit.

Lilly said Genesis was claiming to sell compounded tirzepatide with vitamin B12, and that such combinations are “untested, unproven, and expose consumers to an unjustifiable risk of harm.”

Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.



Source

German autos sector slashes jobs as economic woes bite
World

German autos sector slashes jobs as economic woes bite

A general view of production lines at the Mercedes-Benz assembly plant on June 4, 2025 in Rastatt, Germany. Florian Wiegand | Getty Images News | Getty Images A perfect storm of industry and economic challenges have weighed on Germany’s autos sector, which has shed tens of thousands of jobs over a one-year stretch to the […]

Read More
French stocks slide as Paris government faces risk of collapse
World

French stocks slide as Paris government faces risk of collapse

European stock markets retreated on Tuesday morning, pulled down by French equities as traders monitored the potential for a no confidence vote in the government next month. France’s CAC 40 index plummeted more than 2% in early deals before paring losses to around 1.75%. The country’s three main opposition parties said they would not back a […]

Read More
‘Our country is in danger’: French PM takes confidence vote gamble over budget woes
World

‘Our country is in danger’: French PM takes confidence vote gamble over budget woes

France’s Prime Minister Francois Bayrou speaks during a press conference in Paris on August 25, 2025. Dimitar Dilkoff | Afp | Getty Images France’s minority government on Tuesday faced the prospect of collapse within weeks, after opposition parties said they would not back Prime Minister Francois Bayrou in a Sept. 8 confidence vote tied to […]

Read More